Want to see XRAY full AI Analyst Report?
XRAY Stock Chart & Stats
$12.93
$0.21(1.65%)
At close: 4:00 PM EDT
$12.93
$0.21(1.65%)
Day’s Range― - ―
52-Week Range$9.41 - $14.86
Previous CloseN/A
Volume3.96M
Average Volume (3M)5.74M
Market Cap
$2.18B
Enterprise Value$4.20K
Total Cash (Recent Filing)$239.00M
Total Debt (Recent Filing)$2.31B
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Oct 29, 2026EPS Estimate
0.32Next Dividend Ex-DateN/A
Dividend Yield5.86%
Share Statistics
EPS (TTM)-2.74
Shares Outstanding199,353,880
10 Day Avg. Volume5,552,147
30 Day Avg. Volume5,740,378
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.70
Price to Sales (P/S)0.62
P/FCF Ratio21.91
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$14.13Price Target Upside9.24% Upside
Rating ConsensusHold
Number of Analyst Covering12
EPS Forecast (FY)1.53
Revenue Forecast (FY)$3.58B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables And Diversified Dental PortfolioRecurring procedure-driven consumables and a broad presence across dental disciplines support repeat demand, while the installed equipment base can generate follow-on purchases, service revenue and workflow-related sales over time.
Positive Cash GenerationPositive operating and free cash flow gives Dentsply Sirona an internal funding source for operations, product development and debt service, providing resilience while management works to restore revenue growth and profitability.
Wellspect Product And Geographic GrowthWellspect’s growth demonstrates that targeted innovation and geographic expansion can still produce traction within the portfolio. Continued adoption of newer products could provide a durable offset to weakness in mature dental categories.
Bears Say
Persistent Revenue Decline And Net LossesSeveral years of declining revenue combined with continuing net losses indicate that the turnaround has not yet restored the earnings base. Persistent top-line pressure can reduce operating leverage and limit the company’s ability to absorb fixed costs.
Elevated Leverage Reduces FlexibilityThe heavier debt burden increases financial risk while profitability remains weak. Higher leverage can constrain investment, acquisitions and shareholder returns, and leaves less flexibility if revenue recovery or cash generation disappoints.
Broad-Based Segment Demand PressureWeakness across operating segments suggests the challenge extends beyond a single product line. Lower volumes in consumables, orthodontics, CAD/CAM and treatment centers could delay the return-to-growth plan and pressure margins as investments continue.
DENTSPLY SIRONA News
XRAY FAQ
What was DENTSPLY SIRONA’s price range in the past 12 months?
DENTSPLY SIRONA lowest stock price was $9.40 and its highest was $14.86 in the past 12 months.
What is DENTSPLY SIRONA’s market cap?
DENTSPLY SIRONA’s market cap is $2.18B.
When is DENTSPLY SIRONA’s upcoming earnings report date?
DENTSPLY SIRONA’s upcoming earnings report date is Oct 29, 2026 which is in 66 days.
How were DENTSPLY SIRONA’s earnings last quarter?
DENTSPLY SIRONA released its earnings results on Aug 06, 2026. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.348 by $0.172.
Is DENTSPLY SIRONA overvalued?
According to Wall Street analysts DENTSPLY SIRONA’s price is currently Undervalued.
Does DENTSPLY SIRONA pay dividends?
DENTSPLY SIRONA pays a Quarterly dividend of $0.16 which represents an annual dividend yield of 5.86%. See more information on DENTSPLY SIRONA dividends here
What is DENTSPLY SIRONA’s EPS estimate?
DENTSPLY SIRONA’s EPS estimate is 0.32.
How many shares outstanding does DENTSPLY SIRONA have?
DENTSPLY SIRONA has 199,353,880 shares outstanding.
What happened to DENTSPLY SIRONA’s price movement after its last earnings report?
DENTSPLY SIRONA reported an EPS of $0.52 in its last earnings report, beating expectations of $0.348. Following the earnings report the stock price went down -7.973%.
Which hedge fund is a major shareholder of DENTSPLY SIRONA?
Currently, no hedge funds are holding shares in XRAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DENTSPLY SIRONA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$14.13 (9.24% Upside)
$14.13 (9.24% Upside)
Blogger Sentiment
Neutral
XRAY Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 10.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $515.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 30.9%
Last 30 Days ▲ 8.7%
Last 30 Days ▲ 8.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.26%
12-Months-Change
Fundamentals
Return on Equity
5.86%
Trailing 12-Months
Asset Growth
-14.25%
Trailing 12-Months
Company Description
DENTSPLY SIRONA
Dentsply Sirona Inc. is a global dental products and technologies company serving dental professionals, laboratories, and clinics. It operates across consumables and equipment/technology used in preventive, restorative, and specialty dentistry, offering products such as dental implants and implant solutions, orthodontic and endodontic products, restorative materials, and digital dentistry systems including CAD/CAM, imaging, and treatment-center equipment, along with related software and services.
XRAY Company Deck
XRAY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call reflected a mixed but constructive tone: management reported near-term top-line pressures across multiple segments (notably OIS and consumables distributor headwinds in EMEA) and acknowledged tariff and geopolitical uncertainties. Offsetting these challenges were stable adjusted EBITDA and EPS, a one-time $44 million tariff refund that materially improved cash flow and EPS, continued strategic investments in sales, clinical education and R&D, expansion of dealer partnerships, and strong Wellspect performance. Management maintained full-year guidance and emphasized that improvements from the return-to-growth action plan should become more visible in Q4 and into 2027. Given balanced operational progress and strategic momentum against ongoing revenue and regional demand headwinds, the overall message is cautiously optimistic but still in turnaround mode.View all XRAY earnings summariesXRAY Net sales Breakdown
15.71% Equipment & Instruments
12.45% CAD/CAM
39.92% Essential Dental Solutions
6.17% Orthodontics
16.93% Implants & Prosthetics
8.83% Wellspect Healthcare
XRAY Stock 12 Month Forecast
Average Price Target
$14.13
▲(9.24% Upside)
Technical Analysis
Ownership Overview
0.72% Insiders
32.71% Mutual Funds
40.99% Other Institutional Investors
1.77% Public Companies and
Individual Investors